Harrow (HROW) Non Operating Income (2013 - 2025)
Harrow (HROW) posted quarterly Non Operating Income of -$5.2 million for Q4 2025, up 21.73% year-over-year from -$4.3 million in Q4 2024, and up 62.16% quarter-over-quarter from -$13.7 million in Q3 2025.
Harrow (HROW) Non Operating Income (2013 - 2025) Analysis & Trends
Harrow's Non Operating Income history runs 13 years deep, the most recent figure standing at -$5.2 million for Q4 2025.
- In Q4 2025, Non Operating Income rose 21.73% year-over-year to -$5.2 million; the TTM figure through Dec 2025 stood at -$31.9 million (down 21.96% YoY), while the FY2025 annual figure was -$31.9 million, down 21.96% from the prior year.
- Non Operating Income for Q4 2025 stood at -$5.2 million, up from -$13.7 million in the prior quarter.
- The five-year high for Non Operating Income was $2.8 million in Q4 2022, with the low at -$13.7 million in Q3 2025.
- The 5-year median for Non Operating Income is -$6.4 million (2022), against an average of -$5.9 million.
- The sharpest annual moves came in 2021 and 2022: Non Operating Income sank 325.32% in 2021, then surged 151.23% in 2022.
- Harrow's Non Operating Income stood at -$5.5 million in 2021, then soared by 151.23% to $2.8 million in 2022, then plunged by 269.71% to -$4.8 million in 2023, then sank by 38.02% to -$6.6 million in 2024, then rose by 21.73% to -$5.2 million in 2025.
- Business Quant data shows HROW's Non Operating Income at -$5.2 million in Q4 2025, -$13.7 million in Q3 2025, and -$6.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Harrow | 1.55 Bn | 1.47 Bn | 50.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.19 Mn |
| Sep 30, 2025 | -13.73 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Mar 31, 2025 | -6.55 Mn |
| Dec 31, 2024 | -6.64 Mn |
| Sep 30, 2024 | -5.52 Mn |
| Jun 30, 2024 | -7.35 Mn |
| Mar 31, 2024 | -6.64 Mn |
| Dec 31, 2023 | -4.81 Mn |
| Sep 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | -6.60 Mn |
| Mar 31, 2023 | -8.14 Mn |
| Dec 31, 2022 | 2.83 Mn |
| Sep 30, 2022 | -6.34 Mn |
| Jun 30, 2022 | -7.89 Mn |
| Mar 31, 2022 | -4.54 Mn |
| Dec 31, 2021 | -5.53 Mn |
| Sep 30, 2021 | -4.61 Mn |
| Jun 30, 2021 | -6.65 Mn |
| Mar 31, 2021 | -2.70 Mn |